Meeting Banner
Abstract #0838

Evaluating multi-site rCBV consistency from DSC-MRI imaging protocols and post-processing software across the NCI Quantitative Imaging Network sites using a Digital Reference Object

Laura C. Bell1, Natenael Semmineh1, Hongyu An2, Cihat Eldeniz2, Richard Wahl2, Kathleen Schmainda3, Melissa Prah3, Bradley Erickson4, Panagiotis Korfiatis4, Chengyue Wu5, Anna Sorace5, Neal Rutledge5, Thomas Yankeelov5, Thomas Chenevert6, Dariya Malyarenko6, Yichu Liu7, Andrew Brenner7, Leland Hu8, Yuxiang Zhou8, Jerrold Boxerman9, Yi-Fen Yen10, Jayashree Kalpathy-Cramer10, Andrew Beers10, Mark Muzi11, Ananth Madhuranthakam12, Marco Pinho12, Brian Johnson12,13, and C. Chad Quarles1

1Barrow Neurological Institute, Phoenix, AZ, United States, 2Washington University in St. Louis, St. Louis, MO, United States, 3Medical College of Wisconsin, Milwaukee, WI, United States, 4Mayo Clinic, Rochester, MN, United States, 5The University of Texas at Austin, Austin, TX, United States, 6University of Michigan, Ann Arbor, MI, United States, 7University of Texas Health Science Center at San Antonio, San Antonio, TX, United States, 8Mayo Clinic, Scottsdale, AZ, United States, 9Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, United States, 10Massachusetts General Hospital, Boston, MA, United States, 11University of Washington, Seattle, WA, United States, 12The University of Texas Southwestern, Dallas, TX, United States, 13Philips, Gainesville, FL, United States

Differences in imaging protocols (IP) and post-processing methods (PM) may influence relative cerebral blood volume (rCBV). Our goal was to leverage a dynamic susceptibility contrast (DSC) DRO to characterize rCBV consistency across 12 sites, focusing on differences due to site-specific IPs and/or PMs. Our results indicate high agreement when one center processes rCBV despite slight variations in the IP. However, substantial disagreement was observed when site-specific software was applied for rCBV measurements. These results have important implications for comparing DSC-MRI data across sites/trials, where PM variability could confound the use of rCBV as a biomarker of therapy response.

This abstract and the presentation materials are available to members only; a login is required.

Join Here